{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:03:51Z","timestamp":1775286231801,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ahj.2021.01.018","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T18:13:07Z","timestamp":1611857587000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)"],"prefix":"10.1016","volume":"235","author":[{"given":"Andrew P.","family":"Ambrosy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar I.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi V.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thida C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon H.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van N.","family":"Selby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshith R.","family":"Avula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse K.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Skarbinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Granowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.01.018_bib0001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2021.01.018_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.7202","article-title":"Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California","author":"Myers","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0004","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0006","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0007","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.01.018_bib0009","article-title":"Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?","author":"Das","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.ahj.2021.01.018_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0011","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0012","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1161\/ATVBAHA.108.171736","article-title":"In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid","volume":"28","author":"Yamada","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0013","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2337\/dc12-0269","article-title":"Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia","volume":"35","author":"Satoh-Asahara","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2021.01.018_bib0014","article-title":"Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?","author":"Darwesh","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ahj.2021.01.018_bib0015","first-page":"e10211","article-title":"Icosapent ethyl - a successful treatment for symptomatic COVID-19 infection","volume":"12","author":"Berger","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ahj.2021.01.018_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7812\/TPP\/15-225","article-title":"The Kaiser Permanente Northern California Adult Member Health Survey","volume":"20","author":"Gordon","year":"2016","journal-title":"Perm J"},{"key":"10.1016\/j.ahj.2021.01.018_bib0017","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0018","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0019","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0020","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1161\/CIRCULATIONAHA.105.577577","article-title":"Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study","volume":"113","author":"Go","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.01.018_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.06.030","article-title":"Comparative effectiveness of statin therapy in chronic kidney disease and acute myocardial infarction: a retrospective cohort study","volume":"128","author":"Smith","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCOUTCOMES.113.000221","article-title":"Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study","volume":"6","author":"Smith","year":"2013","journal-title":"Circulation Cardiovascular quality and outcomes"},{"key":"10.1016\/j.ahj.2021.01.018_bib0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0024","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cct.2011.09.009","article-title":"The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease","volume":"33","author":"Manson","year":"2012","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ahj.2021.01.018_bib0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0026","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3882","article-title":"From containment to mitigation of covid-19 in the US","author":"Parodi","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0028","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2027405","article-title":"Developing safe and effective covid vaccines - operation warp speed's strategy and approach","author":"Slaoui","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41569-020-00439-7","article-title":"The COVID-19 pandemic: a catalyst to improve clinical trials","volume":"17","author":"Gaba","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0031","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0033","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.01.018_bib0034","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"Group","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.01.018_bib0035","doi-asserted-by":"crossref","first-page":"J54","DOI":"10.1093\/eurheartj\/suaa119","article-title":"Beyond cardiovascular medicine: potential future uses of icosapent ethyl","volume":"22","author":"Bhatt","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.ahj.2021.01.018_bib0036","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2021.01.018_bib0037","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ahj.2021.01.018_bib0038","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/met.2014.0137","article-title":"Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): effects upon high-sensitivity c-reactive protein and lipid parameters in patients with metabolic syndrome","volume":"13","author":"Bays","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.ahj.2021.01.018_bib0039","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.1989.122","article-title":"The natural history of medication compliance in a drug trial: limitations of pill counts","volume":"46","author":"Rudd","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2021.01.018_bib0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ajh\/1.3.309","article-title":"Pill count measures of compliance in a drug trial: variability and suitability","volume":"1","author":"Rudd","year":"1988","journal-title":"Am J Hypertens"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:06:39Z","timestamp":1757570799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":40,"alternative-id":["S0002870321000314"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.01.018","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}